Hepion Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Apr 16, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 16, 2024
HEPA$0.07-17.7%Stored close · as of Jul 8, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash | $14,785,880 | $51,189,088 |
| Prepaid expenses | 2,701,960 | 5,306,985 |
| Total current assets | 17,487,840 | 56,496,073 |
| Property and equipment, net | 29,487 | 81,620 |
| Right-of-use assets | 212,878 | 50,585 |
| In-process research and development | — | 3,190,000 |
| Other assets | 364,192 | 426,174 |
| Total assets | $18,094,397 | $60,244,452 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $2,348,829 | $2,665,896 |
| Accrued expenses | 2,439,351 | 4,799,983 |
| Operating lease liabilities, current | 115,916 | 53,614 |
| Short-term portion of contingent consideration | 386,000 | 366,229 |
| Total current liabilities | 5,290,096 | 7,885,722 |
| Contingent consideration, non-current | 1,634,000 | 2,093,771 |
| Deferred tax liability | — | 409,022 |
| Operating lease liabilities, non-current | 93,104 | — |
| Derivative financial instruments—warrants | 3,796,390 | — |
| Total liabilities | 10,813,590 | 10,388,515 |
| Commitments and contingencies (see Note 12) | ||
| Stockholders’ equity: | ||
| Series A convertible preferred stock, stated value $10 per share, 85,581 shares issued and outstanding at December 31, 2023 and 2022, respectively. | 855,808 | 855,808 |
| Series C convertible preferred stock, stated value $1,000 per share, 1,688 and 1,801 shares issued and outstanding at December 31, 2023 and 2022, respectively. | 839,320 | 840,320 |
| Common stock—$0.0001 par value per share; 120,000,000 shares authorized, 4,818,733 and 3,811,481 shares issued and outstanding at December 31, 2023 and 2022, respectively. | 482 | 381 |
| Additional paid-in capital | 230,291,362 | 223,950,940 |
| Accumulated other comprehensive loss | (78,779) | (90,168) |
| Accumulated deficit | (224,627,386) | (175,701,344) |
| Total stockholders’ equity | 7,280,807 | 49,855,937 |
| Total liabilities and stockholders’ equity | $18,094,397 | $60,244,452 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.